Outsourced reps, the brand's risk
A pharma contract sales organization supplies representatives who promote a manufacturer's products, but regulators generally look at the promotion, not at who employs the person delivering it. Statements a contract rep makes about a drug's uses or benefits can be attributed to the manufacturer, and promotion that strays from the approved labeling can create problems with the FDA and, in some cases, under the False Claims Act. Meals, speaker programs, and other things of value given to prescribers raise questions under the federal Anti-Kickback Statute and state laws, and some of these payments must be reported through the federal Open Payments program. A few states and cities also require pharmaceutical sales representatives to be licensed or registered. All of this needs to be reflected in how the engagement is structured.
What the services agreement should settle
The contract between the manufacturer and the sales organization is where most of these risks are assigned. It should say who trains the reps, who approves promotional materials, and how call notes, samples, and prescriber data are handled. Compensation design deserves attention, since incentive pay tied too closely to prescriptions can resemble the arrangements fraud and abuse laws are concerned with. The agreement should also address audits, corrective steps when a rep goes off message, indemnification, and what happens to data and staff when the engagement ends. Ask for the sales organization's compliance policies and training records before signing rather than after a problem.
Employment questions on both sides
Representatives are often employees of the sales organization while working full time on one manufacturer's product, which can raise questions about joint employment, overtime classification, and non-solicitation promises between the companies. Whether reps are exempt from overtime under federal and state law depends on their actual duties and pay, not on the job title. When we review an arrangement, we start with the product, the territories, and the existing contract or term sheet. We then identify the provisions that most often cause disputes and the compliance controls that should exist before reps go into the field. Each side should come away knowing which obligations belong to it in writing.
